NCT01211080 (PIHS) is a clinical trial of Propranolol in Hemangioma, sponsored by Hannover Medical School.

Who is sponsoring NCT01211080?

NCT01211080 is sponsored by Hannover Medical School.

What drugs are being tested in NCT01211080?

Interventions in NCT01211080: Propranolol.

What condition does NCT01211080 study?

NCT01211080 studies Hemangioma.

Is NCT01211080 still recruiting?

NCT01211080 is currently completed. Last updated 9 November 2014.

Last reviewed 2014-11-09 · How we verify

NCT01211080: PIHS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-label, Uncontrolled Study of the Off Label Use of Propranolol for Infancy Hemangiomas to Identify Side Effects

Completed Last updated 9 November 2014

What this trial tests

trial testing Propranolol in Hemangioma in 72 participants. Completed in 1 October 2013.

Timeline

1 August 2008

Primary endpoint
1 October 2013

1 October 2013

Quick facts

Lead sponsor	Hannover Medical School
Status	Completed
Study type	OBSERVATIONAL
Enrollment	72
Start date	1 August 2008
Primary completion	1 October 2013
Estimated completion	1 October 2013
Sites	3 locations across Germany

Drugs / interventions tested

Propranolol (propranolol) — full drug profile →

Conditions studied

Hemangioma — all drugs for Hemangioma →

Sponsor

Hannover Medical School

Who can join

Adults 1 Month to 8 Months, any sex, with Hemangioma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cosmesis of the lesion and surrounding skin
Time frame: Completed 8 months of life
Post treatment cosmetic and defiguration result with a hemangioma specific rating tool for categorical (color, vascularity, height, matte/shiny) and non-categorical data (visual analogue scale for overall appearance) from the Vancouver Burn Scar Scale, the Manchester Scar Scale and the Hamilton Burn scar scale by 3 examiners.
Side effects
Time frame: Completed 8th month of life
Number of Participants with Adverse Events in the cardiovascular, bronchopulmonary and metabolic system as a Measure of Safety and Tolerability

Sponsor's own description

Propranolol use for infancy hemangiomas is of world wide interest due to low cost and presumed efficacy. The investigators hypothesized that the drug ist highly active against growing hemangiomas in problematic sites and that there are little side effects. This observational study was undertaken in an uncontrolled fashion to determine sample size, design and and tools for a later randomized controlled trial on propranolol versus physical therapy (i.e.cryotherapy) which is the most prevalent treatment for the condition. During this initial series side effects and relevant design aspects became evident which warrant expedited reporting.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.
Liu L, Yu J, Liu Y, Xie L, et al · · 2025 · cited 6× · PMID 40443737 · DOI 10.3389/fcell.2025.1572909
Abstracts der 108. Jahrestagung der Deutschen Gesellschaft für Kinder- und Jugendmedizin e.V. (DGKJ).
· 2012 · cited 1× · PMID 32226156 · DOI 10.1007/s00112-012-2738-x

Verify or expand the search:

Other trials of Propranolol

Trials testing the same drug.

NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
NCT07352228 — Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices · Phase 4 · enrolling by invitation
NCT07354126 — Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine · NA · recruiting
NCT06960850 — Effects of Oral Propranolol on Induction-Delivery Interval During Induction of Labour With Oxytocin · NA · not yet recruiting

Other recruiting trials for Hemangioma

Currently open trials in the same condition.

NCT07418294 — Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study · recruiting

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01211080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 9 November 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01211080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing